Loading…
The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia
We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day....
Saved in:
| Published in: | Internal Medicine 2020/11/01, Vol.59(21), pp.2745-2749 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c610t-adedabfc5b012975b9bbd2ef20ead9d8e3cb599ed5fbd33f621d3430caded03c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c610t-adedabfc5b012975b9bbd2ef20ead9d8e3cb599ed5fbd33f621d3430caded03c3 |
| container_end_page | 2749 |
| container_issue | 21 |
| container_start_page | 2745 |
| container_title | Internal Medicine |
| container_volume | 59 |
| creator | Taniguchi, Yasuhiro Takahashi, Naoto Miura, Masatomo Hirase, Chikara Sueda, Sanae Espinoza, Jorge Luis Rai, Shinya Nakayama, Shoko Serizawa, Kentaro Kumode, Takahiro Watatani, Yosaku Morita, Yasuyoshi Tanaka, Hirokazu Matsumura, Itaru |
| description | We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment. |
| doi_str_mv | 10.2169/internalmedicine.4871-20 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7691019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2457263865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c610t-adedabfc5b012975b9bbd2ef20ead9d8e3cb599ed5fbd33f621d3430caded03c3</originalsourceid><addsrcrecordid>eNplkctuEzEYhS0EoqHwCsgS62l9mZs3SGgEtCKoXYS15bH_6TjM2MF2ivIePHA9Soi4bGzJ_s459n8QwpRcMVqLa-sSBKemGYzV1sFV2Ta0YOQZWlFeiqJhvHqOVkTQtmB5uUCvYtwSwttGsJfogrO6pHVFV-jXZgR8O--UTtgP-AZmb6yaDtFGrJzBa_sIAXc2hNEvZ97hlBX3k4qzwp13GlwKKlnv4mKwOYTMOcBfrFMxW7vR9jb5ELF1WOH7jGYF_mnTiLsxeGc1_nqAydscBvvvMFv1Gr0Y1BThzWm_RN8-fdx0N8X67vNt92Fd6JqSVCgDRvWDrnpCmWiqXvS9YTAwAsoI0wLXfSUEmGroDedDzajhJSd6ERKu-SV6f_Td7fs8yuNXJrkLdlbhIL2y8u8bZ0f54B9lUwtKqMgG704Gwf_YQ0xy6_dLMVGysmpYzdu6ylR7pHSeTQwwnBMokUuf8t8-5dKnZCRL3_75wrPwd4EZuDsC25jUA5wBFZLVE_zvXIkcuayniDOpRxUkOP4EU-HELg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2457263865</pqid></control><display><type>article</type><title>The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia</title><source>PubMed Central</source><creator>Taniguchi, Yasuhiro ; Takahashi, Naoto ; Miura, Masatomo ; Hirase, Chikara ; Sueda, Sanae ; Espinoza, Jorge Luis ; Rai, Shinya ; Nakayama, Shoko ; Serizawa, Kentaro ; Kumode, Takahiro ; Watatani, Yosaku ; Morita, Yasuyoshi ; Tanaka, Hirokazu ; Matsumura, Itaru</creator><creatorcontrib>Taniguchi, Yasuhiro ; Takahashi, Naoto ; Miura, Masatomo ; Hirase, Chikara ; Sueda, Sanae ; Espinoza, Jorge Luis ; Rai, Shinya ; Nakayama, Shoko ; Serizawa, Kentaro ; Kumode, Takahiro ; Watatani, Yosaku ; Morita, Yasuyoshi ; Tanaka, Hirokazu ; Matsumura, Itaru</creatorcontrib><description>We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.4871-20</identifier><identifier>PMID: 32641651</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Aniline Compounds - blood ; Aniline Compounds - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; bosutinib ; Case Report ; Chronic myeloid leukemia ; Cirrhosis ; dasatinib ; Dasatinib - blood ; Dasatinib - therapeutic use ; Female ; Hemodialysis ; Humans ; Internal medicine ; Japan ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology ; Liver cirrhosis ; Liver Cirrhosis - physiopathology ; Liver Cirrhosis - therapy ; Liver diseases ; Male ; Middle Aged ; Myeloid leukemia ; Nitriles - blood ; Nitriles - therapeutic use ; Plasma ; plasma concentrations ; Protein Kinase Inhibitors - blood ; Quinolines - blood ; Quinolines - therapeutic use ; Renal Dialysis ; Renal function ; Renal Insufficiency - physiopathology ; Renal Insufficiency - therapy ; Treatment Outcome ; Tyrosine kinase inhibitors</subject><ispartof>Internal Medicine, 2020/11/01, Vol.59(21), pp.2745-2749</ispartof><rights>2020 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><rights>Copyright © 2020 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c610t-adedabfc5b012975b9bbd2ef20ead9d8e3cb599ed5fbd33f621d3430caded03c3</citedby><cites>FETCH-LOGICAL-c610t-adedabfc5b012975b9bbd2ef20ead9d8e3cb599ed5fbd33f621d3430caded03c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691019/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691019/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32641651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taniguchi, Yasuhiro</creatorcontrib><creatorcontrib>Takahashi, Naoto</creatorcontrib><creatorcontrib>Miura, Masatomo</creatorcontrib><creatorcontrib>Hirase, Chikara</creatorcontrib><creatorcontrib>Sueda, Sanae</creatorcontrib><creatorcontrib>Espinoza, Jorge Luis</creatorcontrib><creatorcontrib>Rai, Shinya</creatorcontrib><creatorcontrib>Nakayama, Shoko</creatorcontrib><creatorcontrib>Serizawa, Kentaro</creatorcontrib><creatorcontrib>Kumode, Takahiro</creatorcontrib><creatorcontrib>Watatani, Yosaku</creatorcontrib><creatorcontrib>Morita, Yasuyoshi</creatorcontrib><creatorcontrib>Tanaka, Hirokazu</creatorcontrib><creatorcontrib>Matsumura, Itaru</creatorcontrib><title>The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aniline Compounds - blood</subject><subject>Aniline Compounds - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>bosutinib</subject><subject>Case Report</subject><subject>Chronic myeloid leukemia</subject><subject>Cirrhosis</subject><subject>dasatinib</subject><subject>Dasatinib - blood</subject><subject>Dasatinib - therapeutic use</subject><subject>Female</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Japan</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - physiopathology</subject><subject>Liver Cirrhosis - therapy</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myeloid leukemia</subject><subject>Nitriles - blood</subject><subject>Nitriles - therapeutic use</subject><subject>Plasma</subject><subject>plasma concentrations</subject><subject>Protein Kinase Inhibitors - blood</subject><subject>Quinolines - blood</subject><subject>Quinolines - therapeutic use</subject><subject>Renal Dialysis</subject><subject>Renal function</subject><subject>Renal Insufficiency - physiopathology</subject><subject>Renal Insufficiency - therapy</subject><subject>Treatment Outcome</subject><subject>Tyrosine kinase inhibitors</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNplkctuEzEYhS0EoqHwCsgS62l9mZs3SGgEtCKoXYS15bH_6TjM2MF2ivIePHA9Soi4bGzJ_s459n8QwpRcMVqLa-sSBKemGYzV1sFV2Ta0YOQZWlFeiqJhvHqOVkTQtmB5uUCvYtwSwttGsJfogrO6pHVFV-jXZgR8O--UTtgP-AZmb6yaDtFGrJzBa_sIAXc2hNEvZ97hlBX3k4qzwp13GlwKKlnv4mKwOYTMOcBfrFMxW7vR9jb5ELF1WOH7jGYF_mnTiLsxeGc1_nqAydscBvvvMFv1Gr0Y1BThzWm_RN8-fdx0N8X67vNt92Fd6JqSVCgDRvWDrnpCmWiqXvS9YTAwAsoI0wLXfSUEmGroDedDzajhJSd6ERKu-SV6f_Td7fs8yuNXJrkLdlbhIL2y8u8bZ0f54B9lUwtKqMgG704Gwf_YQ0xy6_dLMVGysmpYzdu6ylR7pHSeTQwwnBMokUuf8t8-5dKnZCRL3_75wrPwd4EZuDsC25jUA5wBFZLVE_zvXIkcuayniDOpRxUkOP4EU-HELg</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Taniguchi, Yasuhiro</creator><creator>Takahashi, Naoto</creator><creator>Miura, Masatomo</creator><creator>Hirase, Chikara</creator><creator>Sueda, Sanae</creator><creator>Espinoza, Jorge Luis</creator><creator>Rai, Shinya</creator><creator>Nakayama, Shoko</creator><creator>Serizawa, Kentaro</creator><creator>Kumode, Takahiro</creator><creator>Watatani, Yosaku</creator><creator>Morita, Yasuyoshi</creator><creator>Tanaka, Hirokazu</creator><creator>Matsumura, Itaru</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20201101</creationdate><title>The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia</title><author>Taniguchi, Yasuhiro ; Takahashi, Naoto ; Miura, Masatomo ; Hirase, Chikara ; Sueda, Sanae ; Espinoza, Jorge Luis ; Rai, Shinya ; Nakayama, Shoko ; Serizawa, Kentaro ; Kumode, Takahiro ; Watatani, Yosaku ; Morita, Yasuyoshi ; Tanaka, Hirokazu ; Matsumura, Itaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c610t-adedabfc5b012975b9bbd2ef20ead9d8e3cb599ed5fbd33f621d3430caded03c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aniline Compounds - blood</topic><topic>Aniline Compounds - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>bosutinib</topic><topic>Case Report</topic><topic>Chronic myeloid leukemia</topic><topic>Cirrhosis</topic><topic>dasatinib</topic><topic>Dasatinib - blood</topic><topic>Dasatinib - therapeutic use</topic><topic>Female</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Japan</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - physiopathology</topic><topic>Liver Cirrhosis - therapy</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myeloid leukemia</topic><topic>Nitriles - blood</topic><topic>Nitriles - therapeutic use</topic><topic>Plasma</topic><topic>plasma concentrations</topic><topic>Protein Kinase Inhibitors - blood</topic><topic>Quinolines - blood</topic><topic>Quinolines - therapeutic use</topic><topic>Renal Dialysis</topic><topic>Renal function</topic><topic>Renal Insufficiency - physiopathology</topic><topic>Renal Insufficiency - therapy</topic><topic>Treatment Outcome</topic><topic>Tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taniguchi, Yasuhiro</creatorcontrib><creatorcontrib>Takahashi, Naoto</creatorcontrib><creatorcontrib>Miura, Masatomo</creatorcontrib><creatorcontrib>Hirase, Chikara</creatorcontrib><creatorcontrib>Sueda, Sanae</creatorcontrib><creatorcontrib>Espinoza, Jorge Luis</creatorcontrib><creatorcontrib>Rai, Shinya</creatorcontrib><creatorcontrib>Nakayama, Shoko</creatorcontrib><creatorcontrib>Serizawa, Kentaro</creatorcontrib><creatorcontrib>Kumode, Takahiro</creatorcontrib><creatorcontrib>Watatani, Yosaku</creatorcontrib><creatorcontrib>Morita, Yasuyoshi</creatorcontrib><creatorcontrib>Tanaka, Hirokazu</creatorcontrib><creatorcontrib>Matsumura, Itaru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taniguchi, Yasuhiro</au><au>Takahashi, Naoto</au><au>Miura, Masatomo</au><au>Hirase, Chikara</au><au>Sueda, Sanae</au><au>Espinoza, Jorge Luis</au><au>Rai, Shinya</au><au>Nakayama, Shoko</au><au>Serizawa, Kentaro</au><au>Kumode, Takahiro</au><au>Watatani, Yosaku</au><au>Morita, Yasuyoshi</au><au>Tanaka, Hirokazu</au><au>Matsumura, Itaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>59</volume><issue>21</issue><spage>2745</spage><epage>2749</epage><pages>2745-2749</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>32641651</pmid><doi>10.2169/internalmedicine.4871-20</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2020/11/01, Vol.59(21), pp.2745-2749 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7691019 |
| source | PubMed Central |
| subjects | Adult Aged Aged, 80 and over Aniline Compounds - blood Aniline Compounds - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use bosutinib Case Report Chronic myeloid leukemia Cirrhosis dasatinib Dasatinib - blood Dasatinib - therapeutic use Female Hemodialysis Humans Internal medicine Japan Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology Liver cirrhosis Liver Cirrhosis - physiopathology Liver Cirrhosis - therapy Liver diseases Male Middle Aged Myeloid leukemia Nitriles - blood Nitriles - therapeutic use Plasma plasma concentrations Protein Kinase Inhibitors - blood Quinolines - blood Quinolines - therapeutic use Renal Dialysis Renal function Renal Insufficiency - physiopathology Renal Insufficiency - therapy Treatment Outcome Tyrosine kinase inhibitors |
| title | The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T09%3A37%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Hemodialysis%20and%20Liver%20Cirrhosis%20on%20the%20Plasma%20Concentrations%20of%20Tyrosine%20Kinase%20Inhibitors%20in%20a%20Patient%20with%20Chronic%20Myeloid%20Leukemia&rft.jtitle=Internal%20Medicine&rft.au=Taniguchi,%20Yasuhiro&rft.date=2020-11-01&rft.volume=59&rft.issue=21&rft.spage=2745&rft.epage=2749&rft.pages=2745-2749&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.4871-20&rft_dat=%3Cproquest_pubme%3E2457263865%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c610t-adedabfc5b012975b9bbd2ef20ead9d8e3cb599ed5fbd33f621d3430caded03c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2457263865&rft_id=info:pmid/32641651&rfr_iscdi=true |